Loading...
The standard of care for childhood peanut allergy is lifelong peanut avoidance with immediate access to self-injectable epinephrine. Studies show promise for peanut desensitization, but there is no standardized product available.
In an industry-funded, phase III study, 551 patients (496 aged 4–17 years) with peanut allergy who reacted to ≤100 mg of peanut protein (approximately one third of a peanut) were randomized in a 3:1 ratio to an investigational peanut powder or placebo that was given in a dose-escalating program over 1 year. On day 1, patients underwent a supervised dose escalation phase from 0.5 to 6 mg. The dose was maintained at home, then increased every 2 weeks in clinic up to a daily dose of 300 mg.
After 12 months, 67% of patie…